Immune response
Gene:
MAGEA3 (official gene symbol)Other symbol:
MAGEA3CT family:
CT1CT identifier:
CT1.3Aliases from NCBI:
HIP8 , HYPD , MAGE3 , MGC14613Humoral immune response
Spontaneous humoral immune responses against MAGEA3 have been detected in cancer patients.
| Tumor type | Tumor stage | Frequency | Antibody detection methodology | PMID |
|---|---|---|---|---|
| Breast carcinoma | 0/100(0%) | ELISA | 16094643 | |
| Colorectal carcinoma | 6/74(8.1%) | SEREX | 12124339 | |
| Adult T-cell leukemia/lymphoma (ATLL) | 1/43 (2%) | ELISA | 22323448 | |
| Non-Hodgkin�s lymphoma | 4/97 (4%) | ELISA | 22638551 | |
| Light-chain amyloidosis (AL amyloidosis) | 1/35 (3%) | ELISA | 22983433 | |
| Adenocarcinoma of the large intestine | 2.4% | ELISA | 23390371 |
Cellular immune response
MAGEA3 was identified by its ability to be recognized by CTLs (Gaugler et al., 1994).
MAGEA3-specific CD4 T cell response were detected in healthy donors and in lung cancer patients (Tsuji et al., 2009 PMID: 19734225) as well as in head and neck squamous cell carcinoma patients (Cesson et al., 2010 PMID: 20857101). Naturally occuring cellular immune reponses against MAGEA3 are low and rarely detected in cancer patients, nevertheless several MAGEA3 epitopes recognized by T cells have been identified after stimulation of lymphocytes in vitro (Cancer Immunity Peptide Database).
| HLA | HLA Frequency (%) | Peptide | Position | Lymphocyte Stimulation Method |
PMID |
|---|---|---|---|---|---|
| A1 | 26 | EVDPIGHLY | 168-176 | autologous tumor cells | 8113684 |
| A2 | 44 | FLWGPRALV | 271-279 | peptide | 7805731 |
| A2 | 44 | KVAELVHFL | 112-120 | peptide | 9544234 |
| A24 | 20 | TFPDLESEF | 97-105 | peptide | 10209953 |
| A24 | 20 | VAELVHFLL | 113-121 | peptide | 16446550 |
| B18 | 6 | MEVDPIGHLY | 167-176 | adeno-dendritic cells | 12366779 |
| B35 | 20 | EVDPIGHLY | 168-176 | poxvirus-dendritic cells | 11260504 |
| B37 | 3 | REPVTKAEML | 127-136 | autologous tumor cells | 10363990 |
| B40 | 6 | AELVHFLLL | 114-122 | adeno-dendritic cells | 11854353 |
| B44 | 21 | MEVDPIGHLY | 167-176 | peptide | 8606058 |
| B52 | 5 | WQYFFPVIF | 143-151 | retrovirus-dendritic cells | 10681453 |
| Cw7 | 41 | EGDCAPEEK | 212-220 | lentivirus-dendritic cells | 14764691 |
| DP4 | 75 | KKLLTQHFVQENYLEY | 243-258 | protein | 11103782 |
| DQ6 | 63 | KKLLTQHFVQENYLEY | 243-258 | peptide | 14707109 |
| DR1 | 18 | ACYEFLWGPRALVETS | 267-282 | protein | 12817001 |
| DR4 | 24 | VIFSKASSSLQL | 149-160 | peptide | 11406551 |
| DR7 | 25 | VIFSKASSSLQL | 149-160 | peptide | 11406551 |
| DR11 | 25 | GDNQIMPKAGLLIIV | 191-205 | peptide | 12393675 |
| DR11 | 25 | TSYVKVLHHMVKISG | 281-295 | protein | 10049951 |
| DR13 | 19 | AELVHFLLLKYRAR | 114-127 | protein | 10049940 |
| DR13 | 19 | LLKYRAREPVTKAE | 121-134 | protein | 10049940 |
Induced immune response
A great number of initial immunization clinical trials using MAGEA3 evaluated induction of immune responses in cancer patients, specially in melanoma patients, where it is highly expressed. Even tough spontaneous immune reponses against MAGEA3 are not strong it is one of the best characterized and most frequent expressed cancer testis antigen in tumors. Therefore it is an important target for cancer vaccines.
| Immunogen | PMID |
|---|---|
| MAGE-3 and MAGE-n-derived peptides | |
| ALVAC canarypox virus containing a MAGE-A3 minigene | |
| MAGEA3 protein plus adjuvant | |
| MAGEA3 protein | |
| MAGEA3 peptides | |
| Fusion proteins containing MAGEA3 | |
| Recombinant viruses expressing MAGEA3 protein or ppetides | |
| Dendritic cells pulsed with MAGEA3 protein or peptides | |
| Vaccines containing multiple proteins or peptides including MAGEA3 | |
| MAGE-A3 ASCI | |
| Mage3/Heat Shock Protein70 DNA |